Document is current

Any future updates will be listed below

Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non–small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1186/s43046-026-00414-2

Published Online: 2026-09-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark